Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.69 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.69 |
| ▸ | LMNA | P02545 | 2/20 | 0.69 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.63 |
| ▸ | PGR | P06401 | 1/20 | 0.63 |
| ▸ | PKM | P14618 | 3/20 | 0.61 |
| ▸ | MAPT | P10636 | 4/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | BLM | P54132 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | GFER | P55789 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.57 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.57 |
| ▸ | PLAU | P00749 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL790294 | 0.88 | GAA (0.86) | GAAMAPK1LMNACYP19A1ALDH1A1 | |
| SCHEMBL812663 | 0.83 | PGR (0.82) | GAAMAPK1LMNACYP19A1ALDH1A1 | |
| SCHEMBL32679643 | 0.83 | GAA (0.78) | GAAMAPK1LMNACYP19A1ALDH1A1 | |
| SCHEMBL5044708 | 0.81 | CYP19A1 (0.66) | GAAMAPK1LMNACYP19A1ALDH1A1 | |
| SCHEMBL7564170 | 0.81 | GAA (0.76) | GAAMAPK1LMNACYP19A1ALDH1A1 | |
| SCHEMBL29031235 | 0.81 | PGR (0.85) | GAAMAPK1LMNACYP19A1ALDH1A1 | |
| SCHEMBL30434229 | 0.81 | GAA (0.76) | GAAMAPK1LMNACYP19A1ALDH1A1 | |
| SCHEMBL806437 | 0.81 | GAA (0.76) | GAAMAPK1LMNACYP19A1ALDH1A1 | |
| SCHEMBL3277692 | 0.81 | CA12 (0.68) | GAAMAPK1LMNAALDH1A1MAPT | |
| SCHEMBL2240982 | 0.80 | LMNA (0.73) | GAAMAPK1LMNACYP19A1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113149885-A | EBNA1 inhibitors and methods of using the same | 威斯塔解剖学和生物学研究所 | 2021-07-23 | — | — | CN | claimed |
| US-20180305312-A1 | EBNA1 INHIBITORS AND METHODS USING SAME | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-10-25 | — | — | US | claimed |
| EP-3294705-A1 | EBNA1 INHIBITORS AND METHODS USING SAME | The Wistar Institute Of Anatomy And Biology (US) | 2018-03-21 | — | — | EP | claimed |
| WO-2016183534-A1 | EBNA1 INHIBITORS AND METHODS USING SAME | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2016-11-17 | — | — | WO | claimed |
| US-11912659-B2 | EBNA1 inhibitors and methods using same | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2024-02-27 | — | — | US | disclosed |
| CN-113149885-A | EBNA1 inhibitors and methods of using the same | 威斯塔解剖学和生物学研究所 | 2021-07-23 | — | — | CN | disclosed |
| EP-3294705-B1 | EBNA1 INHIBITORS AND METHODS USING SAME | WISTAR INST (US) | 2021-07-21 | — | — | EP | disclosed |
| US-10981867-B2 | EBNA1 inhibitors and methods using same | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2021-04-20 | — | — | US | disclosed |
| CN-107848964-B | EBNA1 inhibitors and methods of using the same | 威斯塔解剖学和生物学研究所 | 2021-03-19 | — | — | CN | disclosed |
| US-20200239415-A1 | EBNA1 INHIBITORS AND METHODS USING SAME | WISTAR INST (US) | 2020-07-30 | — | — | US | disclosed |
| US-10442763-B2 | EBNA1 inhibitors and methods using same | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2019-10-15 | — | — | US | disclosed |
| US-20180305312-A1 | EBNA1 INHIBITORS AND METHODS USING SAME | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-10-25 | — | — | US | disclosed |
| US-20030105123-A1 | For therapy of respiratory system disorders | ALTANA PHARMA AG (DE) | 2003-06-05 | — | — | US | disclosed |
| EP-1250325-A1 | PHENANTHRIDINE-N-OXIDES | ALTANA Pharma AG (DE) | 2002-10-23 | — | — | EP | disclosed |
| EP-0889886-B1 | NOVEL PHENANTHRIDINES SUBSTITUTED IN THE 6 POSITION | ALTANA PHARMA AG (DE) | 2002-09-18 | — | — | EP | disclosed |
| WO-2001051470-A1 | PHENANTHRIDINE-N-OXIDES | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 2001-07-19 | — | — | WO | disclosed |
| US-6127378-A | A PHOSPHODIESTERASE ENZYME INHIBITOR AS BRONCHIAL THERAPEUTICS, AN ANTIINFLAMMATORY AGENT TREATING ASTHMA PROPHYLAXIS, SKIN DISORDERS, INTESTINE DISORDERS, EYE DISORDERS, CENTRAL NERVOUS SYSTEM DISORDERS, JOINTS DISORDERS | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 2000-10-03 | — | — | US | disclosed |
| EP-0889886-A1 | NOVEL PHENANTHRIDINES SUBSTITUTED IN THE 6 POSITION | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1999-01-13 | — | — | EP | disclosed |
| WO-1997035854-A1 | NOVEL PHENANTHRIDINES SUBSTITUTED IN THE 6 POSITION | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1997-10-02 | — | — | WO | disclosed |
| US-5459026-A | N-phosphonoalkylindole derivatives | FUJI PHOTO FILM CO., LTD. (JP) | 1995-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105123-A1 | For therapy of respiratory system disorders | CHRM3, CYP11B1, CYP11B2 | GAA 1996/4885MAPK1 2897/4885LMNA 2520/4885 |
| US-20200239415-A1 | EBNA1 INHIBITORS AND METHODS USING SAME | MLLT1, EBNA1BP2, MALT1 | GAA 2154/4885MAPK1 1220/4885LMNA 897/4885 |
| US-20180305312-A1 | EBNA1 INHIBITORS AND METHODS USING SAME | MLLT1, EBNA1BP2, MALT1 | GAA 2154/4885MAPK1 1220/4885LMNA 897/4885 |
| US-10981867-B2 | EBNA1 inhibitors and methods using same | MLLT1, EBNA1BP2, MALT1 | GAA 2154/4885MAPK1 1220/4885LMNA 897/4885 |
| US-11912659-B2 | EBNA1 inhibitors and methods using same | MLLT1, EBNA1BP2, MALT1 | GAA 2154/4885MAPK1 1220/4885LMNA 897/4885 |
| US-10442763-B2 | EBNA1 inhibitors and methods using same | MLLT1, EBNA1BP2, MALT1 | GAA 2154/4885MAPK1 1220/4885LMNA 897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.